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The Vaccinia virus BTB/kelch protein F3 has been characterized and its effects on virus
replication in vitro and virus virulence in vivo have been determined. The loss of the F3L gene
had no effect on virus growth, plaque phenotype or cytopathic effect in cell culture under the
conditions tested. However, the virulence of a virus lacking F3L in an intradermal model was
reduced compared with controls, and this was demonstrated by a significantly smaller lesion
and alterations to the innate immune response to infection. The predicted molecular mass of
the F3 protein is 56 kDa; however, immunoblotting of infected cell lysates using an antibody
directed against recombinant F3 revealed two proteins of estimated sizes 37 and 25 kDa.
Vaccinia virus (VACV) is a member of the genus Ortho-
poxvirus of the Poxviridae; a family of large double-
stranded DNA viruses that replicate in the cytoplasm
(Moss, 2001). The VACV genome encodes approximately
200 open reading frames (ORFs) (Goebel et al., 1990) with
essential genes located mostly in the central, highly
conserved region of the genome and non-essential genes
in the variable terminal regions (Kotwal & Moss, 1988;
Perkus et al., 1991).
Three genes in the VACV genome encode BTB/kelch
proteins: A55R, C2L and F3L. These proteins contain an
N-terminal BTB (broad-complex, tram-track and bric-a-
brac) and a C-terminal kelch domain. The kelch motif
sequence is 44–56 aa long, usually occurring as four to
seven repeats. Together these form a tertiary structure
known as the b-propeller, with each repeat unit forming a
secondary structure of four anti-parallel b-sheets repre-
senting a single ‘blade’ of the structure (Adams et al.,
2000). The BTB domain mediates protein–protein inter-
actions (Bardwell & Treisman, 1994) and often serves to
homodimerize the protein or heterodimerize with other
BTB domains. A number of BTB/kelch proteins act as
substrate adapters for the ubiquitination machinery, down-
regulating their target protein and thereby influencing a
number of critical cellular pathways (Zhang & Hannink,
2003; Zhang et al., 2004; Angers et al., 2006; Salinas et al.,
2006).
Poxviruses are the only viruses known to encode kelch
proteins, the number of which varies between species:
cowpox virus contains six kelch proteins, ectromelia virus
four and monkeypox virus just one. All the kelch proteins
in variola virus are missing or fragmented (Shchelkunov
et al., 2002). Of the three VACV BTB/kelch proteins, A55
has five kelch repeats, F3 has four and C2 has three.
Previous studies have investigated the phenotype of re-
combinant VACV strains that lack either the C2L or A55R
genes (Pires de Miranda et al., 2003; Beard et al., 2006).
With both these mutants the viral plaque morphology was
altered, infected cells produced fewer cellular projections
and the characteristic Ca
2+-independent adhesion of
VACV-infected cells was reduced. Murine intradermal
infection with either vDC2 or vDA55 produced lesions
significantly larger than those caused by infection with
control viruses. A role for kelch proteins in poxvirus virul-
ence was also suggested by the reports that the sequential
deletion of multiple BTB/kelch genes from cowpox virus
caused a reduction in virulence (Kochneva et al., 2005),
and that one or more BTB/kelch proteins were disrupted
in, or lost from, attenuated strains of sheeppox virus,
goatpox virus and lumpy skin disease virus (Tulman et al.,
2002; Kara et al., 2003).
The goals of this project were to characterize the F3 protein
encoded by VACV Western Reserve (WR), specifically to
determine its effect on virus growth in vitro and virulence
in vivo.
A recombinant VACV lacking the entire ORF of the F3L
gene (vDF3) was generated using transient dominant selec-
tion (Falkner & Moss, 1990). The primers pmb21 (59-CT-
TAAGTTATTGCATCCACCGAGTGA-39) and pmb29 (59-
AGTCAGTCAGTCCAGTACACAGTATTAACAAATATCG-
39) were used in a PCR to generate a 59 flanking region,
and pmb24 (59-AAGCTTGCCTTTTAGGGACAGACCAG-
39) and pmb30 (59-GACTGACTGACTTTCATGGAATA-
TAGGGATGGT-39) were used to generate a 39 flanking
region. The two fragments were then joined by an overlap
extension PCR (Horton et al., 1989) (the overlapping
complementary DNA regions of primers pmb29 and 30
are shown above in bold) and the resulting fragment was
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the Escherichia coli guanine xanthine phosphoribosyl-
transferase (Ecogpt) gene as a selectable marker, to create
plasmid pPB23. Plasmid pPB23 was transfected into
VACV-infected cells, and a deletion and wild-type virus
were isolated as described previously (Beard et al., 2006).
A revertant virus was constructed using the same method.
A 1290 bp PCR product was generated from VACV WR
genomic DNA using primers pmb21 and pmb24,
comprising full-length F3L with flanking regions. This
was cloned into pSJH7 to create plasmid pPB25. This was
transfected into cells infected with vDF3 and plaques of
the revertant virus (vF3-rev) containing the full-length
F3L gene were isolated. The genomes of these viruses
were analysed by PCR, restriction enzyme digestion and
Southern blotting using a probe specific for the F3L gene
and this confirmed that each virus had the predicted
genome structure (data not shown).
The isolation of vDF3 shows that F3L is not essential for
virus replication. The growth properties of vDF3 were
analysed and compared with vF3 and vF3-rev by both one-
step (m.o.i. of 10) and multi-step (m.o.i. of 0.02) growth
curves and no statistical difference was found (data not
shown). There was no discernable difference in the mor-
phology of plaques formed by vDF3 on confluent BS-C-1
cells when compared to vF3 or vF3-rev (Fig. 1a, b) and the
size of the plaques generated was not significantly different
on RK-13, BS-C-1, TK
2143 or CV-1 cell lines (data not
shown). vF3, vDF3 and vF3-rev were used to characterize
the effect of F3 on various aspects of VACV-induced cyto-
pathic effect, including the number of VACV-induced
cellular projections and relative increase in cell motility
(Sanderson et al., 1998), Ca
2+-dependent adhesion to the
extracellular matrix (ECM) (Sanderson & Smith, 1998) and
the number of actin tails produced from the cell surface. In
each case there was no difference found between vF3, vDF3
and vF3-rev (data not shown).
The virulence of vDF3 was examined in both an intranasal
(Alcami & Smith, 1992) and intradermal (Tscharke et al.,
2002) model of VACV infection. There was no significant
difference in weight loss caused by intranasal infection with
vDF3 when compared to vF3 or vF3-rev (5610
3 p.f.u.
per mouse, data not shown); however, in the intradermal
infection model (Fig. 2) vDF3 produced significantly
smaller lesions (P,0.05) than both vF3 and vF3-rev from
days 6 to 9 post-infection (p.i.) (Fig. 2a). To determine the
basis for this difference in viral virulence, the immune cell
populations present in the ears during infection were
analysed using flow cytometry as described previously
(Jacobs et al., 2006). There was no discernable difference in
the proportions of neutrophils, macrophages or CD3 T
cells (CD4
+or CD8
+). However, in comparison to vF3-
and vF3-rev-infected ears, there was a significant increase
in the number of natural killer (NK) cells present in vDF3-
infected ears at 4 days p.i. and a significant decrease in
the number of T cell receptor (TCR)cd cells at 6 days p.i.
(Fig. 2b). All antibodies used in this study have been
described previously (Jacobs et al., 2006). NK cells were
defined as the NK1.1
+ CD3
2 population using fluorescein
isothiocyanate–anti-NK1.1 monoclonal antibody (mAb)
(BD Pharmingen) and phycoerythrin (PE)–anti-CD3 mAb
(BD Pharmingen). TCRcd cells were labelled with PE–anti-
TCRcd mAb (BD Pharmingen).
A rabbit polyclonal antibody to F3 was generated for
protein characterization. The C-terminal 310 aa of the F3
protein (including the kelch repeats central region) was
amplified from VACV WR by PCR using primers pmb39
(59-GAATTCATGGATGAGGATTATG-39) and pmb17
(59-AAGCTTTTATTTACCATCCCATA-39), generating an
EcoRI site (underlined) and start site (bold) at the 59 end of
the gene and a HindIII site at the 39 end (italics). This
product was cloned into pET28(a) (EMD Biosciences) to
introduce DNA encoding a his-tag at the 59 end of the
(a)
(b)
Fig. 1. Plaque phenotypes of VACVs lacking each BTB/kelch
protein. (a) Plaques produced on confluent BS-C-1 cells by vF3,
vDF3, vF3-rev infection (top row) vA55, vDA55, vA55-rev (middle
row) and vC2, vDC2 and vC2-rev (bottom row). Infected cells
were overlaid with DMEM/2.5% fetal bovine serum/1.5% carboxy-
methylcellulose for 2 days at 376C before being stained with
crystal violet. (b) Higher magnification detail of plaque edges under
phase-contrast microscopy.
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formed into Rosetta E. coli cells (EMD Biosciences) and
cultured in Luria–Bertani medium at 37uCt oa nO D 600 of
0.6 before protein expression was induced by the addition
of 1 mM isopropyl b-D-thiogalactoside for 4 h at 30uC.
The his-tagged recombinant protein was purified from the
insoluble fraction of transformed E. coli by denaturation
of the inclusion body in 6 M guanidine hydrochloride,
application of the denatured protein to Ni-NTA beads
(Qiagen) and elution of the protein in 0.5 M imidazole.
Purified protein was used for rabbit polyclonal antibody
production (Harlan Seralabs).
The IgG fraction of the resulting polyclonal serum was
used to identify the F3 protein in infected cell lysates
(Fig. 3). Confluent BS-C-1 cells were infected at 5 p.f.u. per
cell with vF3, vDF3, vF3-rev or mock-infected either in the
presence or absence of the proteasome inhibitor MG132
(10 mM) and the presence or absence of 40 mg cytosine
arabinoside (AraC) ml
21. Cells were harvested 22 h p.i.
and proteins were separated by SDS-PAGE (12% gel)
before being transferred to nitrocellulose and probed with
anti-F3 IgG (1:1000) or rat mAb p37 directed against F13
(1:1000) (Hiller & Weber, 1985). Proteins were visualized
using Enhanced Chemiluminescence (ECL) Plus Western
blotting detection reagents (Amersham Biosciences)
according to the manufacturer’s instructions.
The resulting immunoblot showed two proteins of 37 and
25 kDa present in vF3 and vF3-rev-infected cells but absent
from vDF3-infected and mock-infected cells (Fig. 3a, b).
The intensity of both bands was increased by the addition of
the proteasomal inhibitor MG132 (Fig. 3c). The presence of
the VACV protein F13 (Fig. 3d) was used as an infection
control. At 22 h p.i., infected cells grown in the presence of
DNA replication inhibitor AraC expressed the two F3-
specific bands, albeit at lower intensity, indicating that they
are the products of early gene expression (Fig. 3e, f).
Fig. 2. (a) VACV-induced lesions (mm) in C57BL/6 mice infected
intradermally with the indicated viruses. The horizontal black line
indicates the time points where vDF3 lesions were significantly
smaller than vF3 and vF3-rev. (Student’s t-test, P,0.05). (b)
Percentage of NK1.1
+ CD3
” cells present in infected ears at
4 days p.i and TCRcd
+ cells 6 days p.i. Asterisks indicate signifi-
cance (Student’s t-test, P,0.05), bars represent mean percen-
tage of cells present (n54)±SEM. These data are representative of
two separate experiments.
Fig. 3. Characterization of the F3 protein. Cells were infected at
5 p.f.u. per cell or mock-infected, with or without MG132 (10 mM),
and lysates were analysed by immunoblotting with (a, b) anti-F3
IgG (1:1000). (b) Intentionally overdeveloped image of (a), to
reveal the 25 kDa band more clearly. (c) Immunoblot of lysates
from cells infected with vF3, vDF3 or vF3-rev in the presence of
MG132. (d) Anti-F13 mAb p37 (1:1000). (e) AraC (40 mgm l
”1)
was added at time 0 as indicated and the blot was probed with
anti-F3 antibody (1:1000). (f) Intentionally overexposed image of
(e) to reveal the presence of the 25 kDa band.
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detect the F3 protein in virions purified by sucrose density-
gradient centrifugation (data not shown).
All three BTB/kelch proteins encoded by VACV have now
been characterized in vitro and in vivo. Previous investiga-
tions indicated strong similarities between the viruses
lacking C2L or A55R, however, vDF3 appears to be quite
different. Deletion of either C2L or A55R caused an altera-
tion in viral plaque morphology in which the edges of the
plaque appear less distinct than in wild-type and revertant
controls (Pires de Miranda et al., 2003; Beard et al., 2006).
However, the morphology of vDF3 plaques is indistinguish-
able from that of vF3 and vF3-rev (Fig. 1a, b). Loss of C2L
and A55R each reduced significantly the number of cells that
produce projections late during infection and reduced the
switch from Ca
2+-dependent to Ca
2+-independent ECM
interaction. In contrast, vDF3 has no significant effect on
either of these processes. These results provide the first
indication that the function of F3 protein during viral
infection is distinct from that of either C2 or A55.
The mild attenuation demonstrated by vDF3 in the early
stages of the intradermal infection model (Fig. 2a) is differ-
ent from both vDC2 and vDA55, which both exhibit an
increased lesion size late in infection (Pires de Miranda
et al., 2003; Beard et al., 2006). The flow cytometry data
presented here indicates a link between F3 and the innate
immune response to virus infection. When F3L is deleted
the percentage of NK cells present in the lesion is increased
4 days p.i. and the percentage of TCRcd cells decreased
2 days later (Fig. 2b). Both these cell types function as part
of the innate immune system (Hamerman et al., 2005;
Born et al., 2006) and as such provide a ‘first-line’ defence
against viral infection. An increase in the proportion of NK
cells early during infection could be responsible for an
accelerated immune response and hence earlier decline in
the proportion of TCRcd cells observed at day 6 p.i.
Notably, the levels of TCRcd cells decline after day 4 in this
model (Jacobs et al., 2006). The innate immune response of
the skin to VACV infection is of particular interest as intra-
dermal or subcutaneous inoculation is the most commonly
used route for administering poxvirus-based vaccines. This
environment contains a number of unique immunological
features such as specialized cd-expressing T cells known as
dendritic epidermal T cells (Hayday & Tigelaar, 2003) and
the distinctive antigen presenting cells, Langerhans cells
and dermal dendritic cells (Romani et al., 2006). Vaccinia
virusisknown toexpressmany proteins involvedin modula-
tion of innate immune responses of the host, including the
production of secreted, soluble decoy receptors and inter-
ruption to the intracellular signalling pathways that activate
the transcription factor nuclear factor (NF)-kB( H a g a&
Bowie,2005). Consequently,the role ofF3inthe recruitment
and activation of NK cells and TCRcd cells in the skin in
response to VACV infection is the subject of further study.
Immunoblotting of infected cell lysates revealed 37 and
25 kDa proteins specific to vF3 and vF3-rev lysates
(Fig. 3a), but the absence of any band attributable to
full-length F3 protein (predicted Mr 56). Further work is
under way to identify the provenance of the two bands; the
rabbit polyclonal antibody used was raised to a recombi-
nant F3 protein lacking only the N-terminal 20 kDa, and
therefore cannot aid in further identification of the frag-
ments. The two polypeptides seen may be derived from a
common precursor, or, less likely, might be translated from
different RNAs.
Both F3-specific bands are still apparent, at a relatively
reduced level, in the presence of AraC, indicating that they
are both products of early gene expression. It is also
notable that the relative intensity of both bands is increased
in the presence of the proteasomal inhibitor MG132,
indicating that either they, or factors that regulate the
putative F3 cleavage, are targets for proteasomal degrada-
tion. Previous work showed that the A55R gene encoded a
protein of predicted size (Beard et al., 2006) and the level of
expression of A55 is not affected by the presence of
MG132, emphasizing the differences between these struc-
turally related proteins.
This investigation has shown that the role of the F3 protein
in VACV infection is notably different from that of C2 or
A55, the other two BTB/kelch proteins encoded by the
virus. F3 has no detectable effect on the cytoskeletal organi-
zation of the virus-infected cell but does affect the innate
immune response to intradermal infection of mice. The
mechanisms behind this phenomenon are the subject of
future investigations.
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